GlobeNewswire: InCarda Therapeutics, Inc. Contains the last 10 of 11 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:19:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/11/07/2549475/0/en/Final-Results-from-Phase-2-INSTANT-Trial-of-InRhythm-for-the-Treatment-of-Newly-Diagnosed-and-Recurrent-Paroxysmal-Atrial-Fibrillation-Presented-at-2022-American-Heart-Association-.html?f=22&fvtc=4&fvtv=51607Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions2022-11-07T12:00:00Z<![CDATA[Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial Fibrillation]]>https://www.globenewswire.com/news-release/2022/10/04/2527647/0/en/InCarda-Therapeutics-Announces-Execution-of-Planned-CEO-Transition-to-Drive-Next-Phase-of-Corporate-Growth.html?f=22&fvtc=4&fvtv=51607InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth2022-10-04T11:00:00Z<![CDATA[Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience]]>https://www.globenewswire.com/news-release/2022/07/26/2485731/0/en/InCarda-Therapeutics-Announces-Enrollment-of-First-Patient-in-Pivotal-Phase-3-RESTORE-1-Trial-of-InRhythm-for-the-Treatment-of-Paroxysmal-Atrial-Fibrillation.html?f=22&fvtc=4&fvtv=51607InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation2022-07-26T11:00:00Z<![CDATA[Single Pivotal Phase 3 Trial to Support Filing of New Drug Application]]>https://www.globenewswire.com/news-release/2021/06/23/2251755/0/en/InCarda-Therapeutics-Announces-Positive-End-of-Phase-2-Meeting-with-FDA-for-InRhythm-for-Treatment-of-Atrial-Fibrillation.html?f=22&fvtc=4&fvtv=51607InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation2021-06-23T12:05:00Z<![CDATA[Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application]]>https://www.globenewswire.com/news-release/2021/06/09/2244357/0/en/InCarda-Therapeutics-Provides-Corporate-Update-Highlighting-New-Phase-2-Data-for-InRhythm-Program-Plans-for-Pivotal-Phase-3-Study-and-Expansion-of-Senior-Management-Team.html?f=22&fvtc=4&fvtv=51607InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team2021-06-09T12:05:00Z<![CDATA[Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm]]>https://www.globenewswire.com/news-release/2021/01/19/2160595/0/en/InCarda-Therapeutics-Announces-Enrollment-of-First-U-S-Patient-in-Phase-2-INSTANT-Trial-of-InRhythm-for-Treatment-of-Atrial-Fibrillation.html?f=22&fvtc=4&fvtv=51607InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation2021-01-19T13:05:00Z<![CDATA[Ongoing Trial to Evaluate Optimal Dose Selected from Dose-Ranging Stage of the INSTANT Study for Rapid Conversion of Atrial Fibrillation to Normal Sinus Rhythm Ongoing Trial to Evaluate Optimal Dose Selected from Dose-Ranging Stage of the INSTANT Study for Rapid Conversion of Atrial Fibrillation to Normal Sinus Rhythm]]>https://www.globenewswire.com/news-release/2020/11/13/2126599/0/en/InCarda-Therapeutics-Presents-Positive-New-Data-from-Phase-2-Study-of-InRhythm-in-Patients-with-Paroxysmal-Atrial-Fibrillation-at-American-Heart-Association-Scientific-Sessions-202.html?f=22&fvtc=4&fvtv=51607InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 20202020-11-13T15:00:00Z<![CDATA[Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm]]>https://www.globenewswire.com/news-release/2020/10/21/2111844/0/en/InCarda-Therapeutics-Raises-30-Million-Through-First-Close-of-Series-C-Equity-Financing.html?f=22&fvtc=4&fvtv=51607InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing2020-10-21T12:05:00Z<![CDATA[Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF)]]>https://www.globenewswire.com/news-release/2019/04/03/1796144/0/en/InCarda-Therapeutics-Appoints-Daniel-G-Welch-as-Executive-Chairman-of-Board-of-Directors.html?f=22&fvtc=4&fvtv=51607InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors2019-04-03T12:00:00Z<![CDATA[Former Chairman and CEO of InterMune Brings Extensive Development and Commercialization Experience to Support Continued Advancement of InRhythm™ for Treatment of Atrial Fibrillation Former Chairman and CEO of InterMune Brings Extensive Development and Commercialization Experience to Support Continued Advancement of InRhythm™ for Treatment of Atrial Fibrillation]]>https://www.globenewswire.com/news-release/2019/02/07/1712141/0/en/New-Patent-Issuances-Strengthen-InCarda-Therapeutics-Intellectual-Property-Portfolio-Covering-Novel-Inhaled-Cardiovascular-Therapies.html?f=22&fvtc=4&fvtv=51607New Patent Issuances Strengthen InCarda Therapeutics’ Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies2019-02-07T13:05:00Z<![CDATA[U.S. Patent Broadly Expands Coverage for Inhaled Treatment of Cardiovascular Disease to Include all Class I – IV Antiarrhythmic Drugs]]>